Janney Montgomery Scott LLC Has $13.68 Million Stake in Sanofi $SNY

Janney Montgomery Scott LLC trimmed its stake in Sanofi (NASDAQ:SNY) by 36.0% during the first quarter, Holdings Channel reports. The fund owned 283,918 shares of the company’s stock after selling 159,575 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Sanofi were worth $13,679,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Flagship Harbor Advisors LLC bought a new stake in Sanofi during the fourth quarter worth approximately $25,000. Measured Wealth Private Client Group LLC bought a new position in shares of Sanofi in the third quarter valued at approximately $29,000. Palisade Asset Management LLC bought a new position in shares of Sanofi in the third quarter valued at approximately $30,000. Annis Gardner Whiting Capital Advisors LLC lifted its stake in shares of Sanofi by 544.4% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 696 shares of the company’s stock worth $34,000 after buying an additional 588 shares during the last quarter. Finally, Purpose Unlimited Inc. acquired a new stake in shares of Sanofi in the fourth quarter worth $36,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Citigroup reiterated a “neutral” rating on shares of Sanofi in a research note on Monday, April 13th. BNP Paribas Exane lowered shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 target price for the company. in a research report on Monday, April 20th. Morgan Stanley set a $52.00 price target on shares of Sanofi in a report on Friday, May 1st. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research report on Thursday, March 19th. Finally, Argus upgraded Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $51.00.

Sanofi Trading Down 2.4%

Shares of Sanofi stock opened at $41.63 on Thursday. The company’s fifty day simple moving average is $43.84 and its 200-day simple moving average is $45.90. The company has a market cap of $100.93 billion, a price-to-earnings ratio of 11.63, a PEG ratio of 1.05 and a beta of 0.35. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17. Sanofi has a 1 year low of $40.89 and a 1 year high of $52.68.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which was paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th were given a $2.4225 dividend. The ex-dividend date was Monday, May 4th. This represents a yield of 559.0%. This is a positive change from Sanofi’s previous annual dividend of $2.04. Sanofi’s dividend payout ratio (DPR) is 49.16%.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.